Nevada Board of Pharmacy agenda/workshop materials describe proposed Schedule I additions: N‑pyrrolidino metonitazene and N‑pyrrolidino protonitazene (NAC 453)

Nevada Legislature-posted Board of Pharmacy meeting agenda/workshop materials indicate proposed amendments to NAC 453 to add the nitazene analogs N‑pyrrolidino metonitazene and N‑pyrrolidino protonitazene to Schedule I. This signals additional controlled substance scheduling changes progressing through the state administrative process. If adopted, these substances would be regulated as Schedule I under Nevada’s Uniform Controlled Substances Act implementation (NAC 453), impacting compliance obligations for entities that may handle or encounter these substances (e.g., laboratories, healthcare/controlled-substance registrants, and enforcement).